These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23786462)

  • 1. Reversal of cardiomyopathy with tocilizumab in a case of HIV-negative Castleman's disease.
    Man L; Goudar RK
    Eur J Haematol; 2013 Sep; 91(3):273-276. PubMed ID: 23786462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature.
    Saiki R; Katayama K; Hirabayashi Y; Oda K; Fujimoto M; Murata T; Nakajima A; Dohi K
    BMC Nephrol; 2021 Jun; 22(1):216. PubMed ID: 34107915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody.
    Kawabata H; Kotani S; Matsumura Y; Kondo T; Katsurada T; Haga H; Kadowaki N; Takaori-Kondo A
    Intern Med; 2013; 52(13):1503-7. PubMed ID: 23812199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
    Matsuyama M; Suzuki T; Tsuboi H; Ito S; Mamura M; Goto D; Matsumoto I; Tsutsumi A; Sumida T
    Intern Med; 2007; 46(11):771-4. PubMed ID: 17541233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicentric Castleman's disease associated with IgA vasculitis (Henoch-Schönlein purpura) responding well to tocilizumab: a case report.
    Oshima Y; Hoshino J; Suwabe T; Hayami N; Yamanouchi M; Sekine A; Ueno T; Mizuno H; Yabuuchi J; Imafuku A; Kawada M; Hiramatsu R; Hasegawa E; Sawa N; Takaichi K; Hayashi N; Fujii T; Ubara Y
    Clin Rheumatol; 2017 Mar; 36(3):729-733. PubMed ID: 28168662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
    Koga T; Sumiyoshi R; Kawakami A; Yoshizaki K
    Mod Rheumatol; 2019 Mar; 29(2):302-305. PubMed ID: 30285516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comorbid case of multicentric Castleman's disease and pulmonary hyalinising granuloma successfully treated with tocilizumab and corticosteroid.
    Takeuchi N; Arai T; Kitaichi M; Inoue Y
    BMJ Case Rep; 2013 Sep; 2013():. PubMed ID: 24072826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab for focal segmental glomerulosclerosis secondary to multicentric Castleman's disease.
    Ebisawa K; Masamoto Y; Tokushige J; Nishi H; Honda K; Hinata M; Toyama K; Nangaku M; Kurokawa M
    Ann Hematol; 2019 Aug; 98(8):1995-1997. PubMed ID: 30761408
    [No Abstract]   [Full Text] [Related]  

  • 9. Mixed-type multicentric Castleman's disease developing during a 17-year follow-up of sarcoidosis.
    Awano N; Inomata M; Kondoh K; Satake K; Kamiya H; Moriya A; Ando T; Kumasaka T; Takemura T; Takeuchi K; Ikushima S
    Intern Med; 2012; 51(21):3061-6. PubMed ID: 23124151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful Treatment of TAFRO Syndrome, a Variant of Multicentric Castleman's Disease, with Cyclosporine A: Possible Pathogenetic Contribution of Interleukin-2.
    Konishi Y; Takahashi S; Nishi K; Sakamaki T; Mitani S; Kaneko H; Mizutani C; Ukyo N; Hirata H; Tsudo M
    Tohoku J Exp Med; 2015 Aug; 236(4):289-95. PubMed ID: 26250536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversible cardiomyopathy associated with Multicentric Castleman disease: successful treatment with tocilizumab, an anti-interleukin 6 receptor antibody.
    Kanda J; Kawabata H; Yamaji Y; Ichinohe T; Ishikawa T; Tamura T; Furukawa Y; Kimura T; Kita T; Uchiyama T
    Int J Hematol; 2007 Apr; 85(3):207-11. PubMed ID: 17483056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of a mesangial proliferative glomerulonephritis with interstitial nephritis associated with Castleman's disease by an anti-interleukin-6 receptor antibody (tocilizumab).
    Otani N; Morishita Y; Oh I; Saito O; Takemoto F; Muto S; Kusano E
    Intern Med; 2012; 51(11):1375-8. PubMed ID: 22687845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dyspnoea, cough and B symptoms in a 40-year-old woman].
    Wolfensberger A; Benz R; Russi EW; Tinguely M; Keller C; Gerber B
    Internist (Berl); 2013 Aug; 54(8):1011-5. PubMed ID: 23836253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease.
    Arita Y; Sakata Y; Sudo T; Maeda T; Matsuoka K; Tamai K; Higuchi K; Shioyama W; Nakaoka Y; Kanakura Y; Yamauchi-Takihara K
    Heart Vessels; 2010 Sep; 25(5):444-7. PubMed ID: 20676969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab.
    Higuchi T; Nakanishi T; Takada K; Matsumoto M; Okada M; Horikoshi H; Suzuki K
    J Korean Med Sci; 2010 Sep; 25(9):1364-7. PubMed ID: 20808682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of multicentric Castleman disease through combination of tocilizumab, lenalidomide and glucocorticoids: Case report.
    Cai S; Zhong Z; Li X; Wang HX; Wang L; Zhang M
    Medicine (Baltimore); 2019 Nov; 98(46):e17681. PubMed ID: 31725610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-6-positive classical Hodgkin's lymphoma co-occurring with plasma cell type of Castleman's disease: report of a case.
    Momoi A; Kojima M; Sakai T; Ajiro J; Isahai N; Nagai K; Aoki S
    Int J Hematol; 2013 Feb; 97(2):275-9. PubMed ID: 23359301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tocilizumab treatment of HHV8-positive/HIV-negative, multricentric plasma cell type Castleman's disease].
    Mûzes G; Csomor J; Sipos F
    Magy Onkol; 2016 Nov; 60(4):328-332. PubMed ID: 27898752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idiopathic multicentric Castleman disease with Sjögren's syndrome and secondary membranous nephropathy: a case report and review of the literature.
    Pan Y; Cui Z; Wang S; Zheng D; Deng Z; Tian X; Guo H; Bao W; Zhou S; Wang Y
    BMC Nephrol; 2020 Dec; 21(1):528. PubMed ID: 33276741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
    van Rhee F; Wong RS; Munshi N; Rossi JF; Ke XY; Fosså A; Simpson D; Capra M; Liu T; Hsieh RK; Goh YT; Zhu J; Cho SG; Ren H; Cavet J; Bandekar R; Rothman M; Puchalski TA; Reddy M; van de Velde H; Vermeulen J; Casper C
    Lancet Oncol; 2014 Aug; 15(9):966-74. PubMed ID: 25042199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.